Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis Inc. reports biotechnology developments centered on emavusertib (CA-4948), an orally available small-molecule IRAK4 and FLT3 inhibitor. Company updates focus on oncology programs in lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia, including clinical data presentations, combination approaches with BTK inhibitors, and studies involving venetoclax and azacitidine.
Recurring Curis news also covers quarterly financial and operating results, conference-call updates, capital actions such as private placements, and security-structure matters involving preferred stock and warrants. The company’s public updates combine clinical-program progress with financing, governance and operating disclosures typical of a development-stage biotechnology issuer.
Curis, Inc. (NASDAQ: CRIS) will release its Q4 2021 financial results on February 24, 2022, after U.S. markets close. Management will host a conference call at 4:30 PM ET on the same day. Investors can join the call by dialing (888) 346-6389 (U.S.) or (412) 317-5252 (international). The call will also be available on Curis's website. The company specializes in cancer therapeutics, and its pipeline includes the IRAK4 kinase inhibitor CA-4948, currently in clinical trials for various hematologic malignancies.
Curis, Inc. (NASDAQ: CRIS) announced that CEO James Dentzer will participate in two upcoming conferences: the B. Riley Virtual Oncology Conference on January 27, 2022, at 1:30 p.m. ET, and the SVB Leerink 11th Annual Global Healthcare Conference on February 18, 2022, at 11:20 a.m. ET. Live webcasts of these presentations will be accessible on their website, and archived replays will be available for 90 days afterward.
Curis focuses on innovative cancer therapeutics, including trials on the IRAK4 inhibitor CA-4948.
Curis, Inc. (NASDAQ: CRIS) announced the approval of inducement stock options on January 3, 2022, granting 224,700 shares to eleven new employees. The options have a 10-year term, with vesting over four years based on continued employment. Each grant's exercise price matches the stock's closing price on the grant date, incentivizing new hires as part of the company's growth strategy in cancer therapeutics. Curis focuses on innovating treatments, particularly in immuno-oncology, with several clinical trials underway for its drug candidates.
Curis, Inc. (NASDAQ: CRIS) announced positive clinical data from its ongoing Phase 1/2 study of CA-4948, an IRAK-4 inhibitor, for treating relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). As of December 16, 2021, CA-4948 was well-tolerated, with no dose-limiting toxicities reported, and showed promising anti-cancer activity with a 40% complete response rate in AML patients with specific mutations. Curis also reported initial positive safety data for CI-8993, a monoclonal antibody targeting VISTA, currently in Phase 1 trials for solid tumors.
Curis, Inc. (NASDAQ: CRIS) announced the appointment of three new executives to enhance its management team as of January 3, 2022. Felix Geissler, M.D., Ph.D., becomes Vice President of Medical Affairs; Kimberly Steinmann, M.D., Vice President of Clinical Development; and Dora Ferrari, Vice President of Clinical Operations. These appointments aim to bolster internal capabilities for advancing clinical drug candidates CA-4948 and CI-8993. The company is focused on developing innovative cancer therapeutics and has collaborations for its drug candidates, including ongoing trials.
Curis, Inc. (NASDAQ: CRIS) announced that CEO James Dentzer will present at the H.C. Wainwright BioConnect Conference on January 10, 2022, starting at 7:00 a.m. ET. The presentation will be available for on-demand viewing afterward. A live webcast can be viewed in the Investors section of Curis' website and will remain accessible for 90 days. Curis focuses on developing cancer therapeutics, including collaborations on various oncology treatments, such as the IRAK4 inhibitor CA-4948, currently in trials for non-Hodgkin lymphoma and acute myeloid leukemia.
Curis, Inc. (NASDAQ: CRIS) has been added to the Nasdaq Biotechnology Index and the iShares Biotechnology ETF, effective before market open on December 20, 2021. Curis focuses on innovative cancer therapeutics, with ongoing clinical trials for several drug candidates, including CA-4948, which has received Orphan Drug Designation for acute myeloid leukemia. The company collaborates with Aurigene and ImmuNext, and their partnership with Genentech commercializes Erivedge for advanced basal cell carcinoma.
Curis, Inc. (NASDAQ: CRIS) announced the appointment of John A. Hohneker, M.D., to its Board of Directors on Dec. 6, 2021. Dr. Hohneker brings over 30 years of biopharmaceutical experience, previously serving as President and CEO of Anokion SA and in leadership roles at Novartis. His expertise will support Curis in accelerating drug candidates, particularly the first-in-class IRAK4 inhibitor, CA-4948, currently in clinical trials for various cancers. This appointment is seen as pivotal for Curis's future growth and potential commercialization of its therapies.
Curis (CRIS) announced its Q3 2021 financial results, reporting a net loss of $11.1 million or $0.12 per share, compared to a loss of $6.0 million for Q3 2020. Revenues grew to $3.0 million from $2.7 million year-over-year. The company continues to advance its clinical trials for CA-4948 in AML, MDS, and B cell cancers, with a significant update expected in January 2022. Operating expenses increased to $13.1 million due to higher R&D costs. As of September 30, 2021, Curis had $149.8 million in cash, ensuring planned operations into 2024.
Curis, Inc. (NASDAQ: CRIS) announced new preclinical data for its investigational monoclonal antibody, CI-8993, at the Society for Immunotherapy of Cancer's 36th Annual Meeting. CI-8993 targets the immune checkpoint molecule VISTA, with a study conducted in collaboration with the Olivia Newton-John Cancer Research Institute confirming its binding properties. Future plans include a clinical trial involving patients with solid tumors. This research aligns with Curis's commitment to advancing cancer therapies and supports ongoing development in immuno-oncology.